Table 5.
Relative effect sizes from the fixed effect model for mean change in systolic blood pressure (mmHg)
| Regimen | Change in SBP from baseline (mmHg) | |
|---|---|---|
| Fixed effect model | ||
| All vs. liraglutide 1.2 mg QD | Exenatide QW vs. all | |
| Mean (95% CrI) | Mean (95% CrI) | |
| Liraglutide 1.2 mg QD | N/A | −2.13 (−5.22, 0.96) |
| Dulaglutide 1.5 mg QW | 0.27 (−2.72, 3.25) | −2.40 (−6.41, 1.62) |
| Liraglutide 1.8 mg QD | 0.81 (−1.46, 3.08) | −2.94 (−6.45, 0.58) |
| Exenatide 2 mg QW | −2.13 (−5.22, 0.96) | N/A |
CrI credible interval, N/A not applicable, QD once daily, QW once weekly, SBP systolic blood pressure
* Statistically significant difference. Note: the random effects model is not reported as there was not enough information to estimate the between-study standard deviation